Celltrion to deliver three treatments to Peru
Truxima, Herzuma, and Yuflyma won the bids from the Peruvian Ministry of Health and National Workers' Insurance Fund
By Feb 15, 2024 (Gmt+09:00)
Hankook Tire buys $1 bn Hanon Systems stake from Hahn & Co.
NPS to hike risky asset purchases under simplified allocation system
Osstem to buy Brazil’s No. 3 dental implant maker Implacil
S.Korea's LS Materials set to boost earnings ahead of IPO process
UAE to invest up to $1 bn in S.Korean ventures
South Korea’s Celltrion Inc. announced on Thursday that it will supply three treatments, including its blood cancer drug Truxima (rituximab) to Peru.
It will be supplied to CENARES in two installments (500mg) and to EsSalud for a year (100mg), capturing over half of the overall Peruvian market for this drug, encompassing both biosimilar and original versions.
The company also won bids for anticancer biosimilars Herzuma (trastuzumab) for breast and Yuflyma (adalimumab) for the treatment of autoimmune diseases.
These wins grant Celltrion a dominant 53% share of the Peruvian Trastuzumab market and a solid 20% share of the adalimumab market.
Celltrion plans to launch two additional biosimilars in Peru later this year: Remsima SC (subcutaneous injection for autoimmune diseases) in mid-2024 and Vegzelma (for colorectal and non-small cell lung cancer) by year-end.
Write to Dae-Kyu Ahn at powerzanic@hankyung.com
-
Bio & PharmaCelltrion, WuXi XDC to develop new antibody-drug conjugates
Jan 24, 2024 (Gmt+09:00)
1 Min read -
Bio & PharmaCelltrion to export three anticancer drugs to Europe
Jan 18, 2024 (Gmt+09:00)
1 Min read -
Bio & PharmaCelltrion Holdings eyes Nasdaq IPO by early 2025: chairman
Jan 16, 2024 (Gmt+09:00)
1 Min read